Ajanta Pharma Limited (AJANTPHARM) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE031B01049
Key metrics
- Market Cap
- ₹45,610 Cr
- P/E Ratio
- 40.27
- EPS
- 90.63
- Book Value
- 362.35
- P/B Ratio
- 10.2
- ROE
- 23.33%
- ROCE
- 27.71%
- Debt / Equity
- 0.06
- Net Margin
- 19.53%
- Revenue Growth
- 17.87%
- Profit Growth
- 14.73%
- Dividend Yield
- 1.76%
- 52W High
- ₹3,796.00
- 52W Low
- ₹2,329.90
- Market Cap Band
- large cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Promoter Holding
- 54.3%
The full Ajanta Pharma Limited analysis
Create a free account to open the complete AJANTPHARM deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.